Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$11.65 USD
-0.11 (-0.94%)
Updated Aug 26, 2024 04:00 PM ET
After-Market: $11.66 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Amicus Therapeutics (FOLD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$17.18 | $20.00 | $13.00 | 46.09% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Amicus Therapeutics comes to $17.18. The forecasts range from a low of $13.00 to a high of $20.00. The average price target represents an increase of 46.09% from the last closing price of $11.76.
Analyst Price Targets (11)
Broker Rating
Amicus Therapeutics currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, 10 are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 10 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/9/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
8/9/2024 | Needham & Company | Gil J Blum | Hold | Hold |
8/8/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
6/30/2024 | Goldman Sachs | Salveen Richter | Hold | Hold |
5/30/2024 | Wells Fargo Securities | Tiago Fauth | Not Available | Strong Buy |
5/14/2024 | Guggenheim Securities | Debjit Chattopadhyay | Not Available | Strong Buy |
5/10/2024 | UBS | Eliana Merle | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 12 |
Average Target Price | $17.18 |
LT Growth Rate | 45.20% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | 0.07 |